CSPC Zhongqi Pharmaceutical Technology Co.

Shijiazhuang, China

CSPC Zhongqi Pharmaceutical Technology Co.

Shijiazhuang, China
SEARCH FILTERS
Time filter
Source Type

Wen T.-J.,Hebei Medical University | Gao Y.,Hebei Medical University | Chen N.-N.,Hebei Medical University | Wang Y.-J.,CSPC Zhongqi Pharmaceutical Technology CO. | And 3 more authors.
Chinese Pharmaceutical Journal | Year: 2015

OBJECTIVE: To explore the feasibility of the reversal of multidrug resistance in breast cancer using vector-based small interference RNA(siRNA) and to solve the problems of siRNA transient expression and siRNA delivery in vivo. METHODS: Based on the siRNA sequence which was screened in previous studies that could effectively inhibit the expression of MDR1 gene, the expression plasmid was constructed. The siRNA expression plasmid was then encapsulated in new nano-sized stealth cationic liposomes. Pharmacodynamic studies of the liposomes were carried out in vitro and in vivo. RESULTS: The results showed that the cationic liposomes loaded with MDR1 siRNA expression plasmid could effectively inhibit the expression of MDR1 gene both in vitro and in vivo. CONCLUSION: Multi-drug resistance of breast cancer cells is reversed to a great extent by this siRNA-containing cationic liposomes. Nano-sized cationic liposomes are ideal delivery vehicle of siRNA, which could protect the siRNA from degradation and deliver siRNA into the tumor region where it could exert functions. Copyright 2015 by the Chinese Pharmaceutical Association.


Wang H.,Hebei Medical University | Hu L.,Hebei University | Li C.,CSPC ZhongQi Pharmaceutical Technology Co. | Zhang J.,Hebei University | Zhang T.,Hebei University
Pharmazie | Year: 2011

In this study, doxorubicin (DOX)-loaded long circulating liposomes combined with curcumin (CUR) (DOX-CUR-LCLs) were successfully prepared as a novel formulation for cancer treatment. The particle size and distribution, zeta potential, drug loading capacity, and entrapment efficiency (EE) of the preparation were characterized. The in vitro anti-tumor activities of DOX-CUR-LCLs and DOX-LCLs against A549 cells were then evaluated and compared with that of free DOX. Cytotoxicity evaluation showed that DOX-CUR-LCLs had a significantly higher antitumor activity than other DOX preparations. These results suggest that novel DOX-CUR-LCLs, combination of DOX and CUR administered in long-circulating liposomes, could improve antitumor activity.


Zhang Y.-H.,Suzhou Industrial Park Center for Disease Control and Prevention | Yu L.-G.,Suzhou Industrial Park Center for Disease Control and Prevention | Zhu W.-Z.,Suzhou Industrial Park Center for Disease Control and Prevention | Wang S.-L.,Suzhou Industrial Park Center for Disease Control and Prevention | And 3 more authors.
Asian Pacific Journal of Cancer Prevention | Year: 2014

The objective of the present study was to investigate cloning, expression, and functions of the recombinant protein, Siva1. Siva1 gene was synthesized by RT-PCR from HCT116 cells. Plasmids were cleaved with the restriction endonuclease, BamH1/Sal1 and products were connected to pQE30, which underwent cleavage by BamH1/Sal1. The recombinant plasmid, pQE30-Siva1, was identified after digestion with restriction endonucleases followed by transformation into E. coli M15. Expression of Siva1 was induced by IPTG and identified by SDSPAGE following purification with affinity chromatography. The results showed that size of Siva1 was 12 kDa, consistent with the molecular weight of the His-Siva1 fusion protein. Functional test demonstrated that Siva1 significantly inhibited the invasion and migration of HCT116 cells. It may thus find clinical application for control of cancers.


Wang L.-F.,CSPC Zhongqi Pharmaceutical Technology Co. | Guo W.-M.,CSPC Zhongqi Pharmaceutical Technology Co. | Yang H.-Y.,CSPC Zhongqi Pharmaceutical Technology Co. | Wang B.-L.,CSPC Zhongqi Pharmaceutical Technology Co.
Chinese Journal of New Drugs | Year: 2014

Objective: To establish a method for determination of three methanesulfonates in SIPI5357 mesylate by GC-MS. Methods: The three methanesulfonates were determined by pre-column derivation technology combined with GC-MS. Results: The resolutions of the three methanesulfonates were greater than 2.0. Linear calibration curves were obtained over the range of 2.0~625.0 ng·mL-1 for all the methanesulfonates(r=0.999 9, n=6). The recoveries were all greater than 99.9% with RSDs less than 3.1%. The detection limits were all lower than 0.375 ng·mL-1. Conclusion: The method was proved to be simple, accurate, rapid, and suitable for determination and quality control of SIPI5357 mesylate.


Yang Y.,Beijing Academy of Agriculture and Forestry Sciences | Yang Y.,Beijing Institute of Pharmacology and Toxicology | Lou K.,Beijing Institute of Pharmacology and Toxicology | Lou K.,CSPC Zhongqi Pharmaceutical Technology Co. | And 3 more authors.
Chromatographia | Year: 2011

A method was developed to determine vinpocetine and its metabolite, apovincaminic acid, in beagle plasma by LC-MS-MS. After protein precipitation with methanol, the supernatant of the sample was concentrated and injected into an Agilent Zorbax XDB-C18 column. The sample was separated by a mobile phase consisting of acetonitrile and 0.2% formic acid solution, and the reading was determined on an Agilent 6410 Triple Quad Tandem mass spectrometer in multiple reaction monitoring mode with the following transitions: m/z 351.5 → 280.2/266.3 for vinpocetine, 323.2 → 236.1/280.2 for apovincaminic acid, and 411.2 → 191.1 for the internal standard. The intra- and inter-day variances were less than 15% (RSD%), and average recoveries were higher than 80%. The linearity ranges (LR) between 0.1 and 20.0 ng mL-1 for vinpocetine (r 2 = 0.9980) and between 1.0 and 200.0 ng mL -1 for apovincaminic acid (r 2 = 0.9995) were established. In summary, this method is sensitive, specific, and appropriate for in vivo study of various dosage forms of vinpocetine. © 2011 Springer-Verlag.


Yang J.,Chinese Academy of Sciences | Shi Y.,Chinese Academy of Sciences | Li C.,CSPC Zhongqi Pharmaceutical Technology Co. | Gui L.,Chinese Academy of Sciences | And 7 more authors.
Cancer Chemotherapy and Pharmacology | Year: 2014

Purpose: Plm60-s is a pegylated liposomal mitoxantrone formulation, in which mitoxantrone was loaded into small unilamellar vesicles (~60 nm) made from solid lipid membrane. This two-arm, dose-escalating phase I study was designed to determine safety and pharmacokinetics of plm60-s, and to compare with those of conventional mitoxantrone injection (c-MI). Methods: Patients received an intravenous infusion of plm60-s at 6, 10, 12, 14, 16 and 18 mg/m2 every 4 weeks. Three or 6 patients were in each group of dose level. If more than one third patients of a group experienced dose-limiting toxicity, dose climbing will stop. The control group of 3 patients received c-MI at 10 mg/m2 every 28 days. Samples for pharmacokinetic studies were collected. The analysis of the safety and tolerability was done according to the record and laboratory examination, etc. Results: Twenty patients were enrolled. One grade 3 leukocytopenia occurred in plm60-s groups. Plm60-s was safer than c-MI at the same dose of 10 mg/m2. Two complete responses and one partial response occurred in plm60-s group. In plasma, plm60-s exhibited sustained release of the content, resulting in the reduced peak concentrations and enhanced AUC of released MIT. Total mitoxantrone was linearly cleared, and mitoxantrone was predominantly in the liposomal encapsulation form. Repeated administration of plm60-s did not affect the clearance kinetics. Conclusions: At a dose of up to 18 mg/m2, plm60-s could be well tolerated and potential efficacy could be observed. The pharmacokinetic profile of plm60-s was remarkably altered. Further investigations are in progression. © 2014 Springer-Verlag.

Loading CSPC Zhongqi Pharmaceutical Technology Co. collaborators
Loading CSPC Zhongqi Pharmaceutical Technology Co. collaborators